Vince Pitetti

We combine dynamic content and responsive design to deliver high-impact, cutting edge websites. We like to think that our clients will not just be satisfied but proud of the final project.

Voorhees, NJ 08043 USA
+1 856 495 3825

Pivot Pharmaceuticals Acquires ERS Holdings for $1 Million Plus Stock

Pivot Pharmaceuticals Acquires ERS Holdings for $1 Million Plus Stock

Vancouver-based Pivot Pharmaceuticals Inc. (PVOTF) signed a Letter Of Intent to acquire cannabis infusion company ERS Holdings LLC. ERS is a California-based private company that has developed a patented technology called RTIC or Ready To Infuse Cannabis. The stock has jumped over 9% on the news and was lately trading at $1.14.

According to the company statement, Pivot will pay ERS $1,000,000 USD and 5,000,000 common shares of Pivot Pharmaceuticals. The shares will be subject to a six-month restriction with the first 25% of the total number of shares to be released six months following the closing date, with 25% to be released every quarter thereafter. Pivot Pharmaceuticals is an emerging biopharmaceutical company that develops and commercializes therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies.

ERS Holdings Background

RTIC was invented by Ross Franklin and Ed Rosenthal and “relates generally to methods and compositions of matter for enabling concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages or food by combining cannabis oil with a starch powder or starch-derived powder.  Embodiments also relate to a variety of culinary uses for the stabilized, emulsified, flavorless concentrated cannabis oil powder.” ERS has also filed several continuation patents relating to the transformation of cannabis oil into powder for infusion into a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions and bottled beverages.

“After being courted by some of Canada’s largest cannabis companies, we selected the Pivot team to help monetize our patent,” said Mr. Franklin, ERS’ CEO. “Their management team has extensive pharmaceutical and nutraceutical industry experience and an impressive track record of bringing products to market.  In addition to the food and beverage markets, we also look forward to integrating ‘RTIC’ into Pivot’s current topical, oral and nanoparticulate pipeline.”

Pivots’ History

Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated, “Pivot believes that the anticipated changes in cannabis regulation in Canada and California will provide an opportunity to launch multiple products into the healthcare and recreational markets in 2018. We are delighted that Ross Franklin and Pat Rolfes from ERS have chosen Pivot to help transform their patents and processes into therapeutic consumer goods. Pivot is in ongoing discussions with several Canadian Licensed Producers and Licensed Dealers in order to accelerate commercialization of our large pipeline of technology-driven products. If a suitable joint venture partner is not identified by January 2018, Pivot will seek a Licensed Dealer designation from Health Canada and commence construction of its own production facility. As a result, Pivot has engaged CBRE, the world’s largest commercial real estate firm, to help facilitate the site selection process.”

Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. conducts research, development, and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care.


The post Pivot Pharmaceuticals Acquires ERS Holdings for $1 Million Plus Stock appeared first on Green Market Report.